Quin Wills
, Founder & CEO, Ochre Bio
Quin is a medical doctor with further degrees in genetics, mathematics, computational biology, and a doctorate in systems genomics, from Oxford and Cambridge Universities. He started his first drug discovery liver genomics company 17 years ago. More recently he founded and led Novo Nordisk’s Advanced Genomics Department, again focused on liver disease. Frustrated with the lack of therapeutic innovation in chronic diseases, Quin co-founded Ochre Bio, a liver RNA therapeutics company that differentiates itself in the ability to generate large-scale human discovery and validation data at its global R&D sites in Europe, Asia, and the U.S. A key innovation from Quin’s team’s at the intersection of dry-lab (machine learning) and wet-lab has been the ability to progress a hit to generating human data on the lead within weeks, not years. They do this using whole human livers that they maintain on machines.
